Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hamdan, Ayad
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24
Patel, Hitendra
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer	Recruiting	1	36	US	Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)	University of California, San Diego, Rigel Pharmaceuticals	Pancreatic Ductal Adenocarcinoma (PDAC)	06/27	12/28
Maroge, Joseph
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24